Zota Health Care Ltd. · NSE:ZOTA
Zota Health Care — Q2 FY21 Earnings Presentation
23 slides from Zota Health Care's earnings presentation, Dec 2, 2020
Slide 1: Investor Presentation cover letter to NSE
} zoto' healthcare ltd. December 02, 2020 To, The Manager Listing Department, The NationalStock Exchange of lndia Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbal - 400051 Dear Sir/Madam, Trading Symbol: ZOTA Sub: lnvestor Presentation Ref: Regulation 30 of SEBI (tisting Obligations
Slide 2: Q2FY21 Performance Highlights
Q4&FY20 Q2FY21 PPerformance E R F O R M A N C E HHighlights IGHLIGHTS December J U N E 2 0 2 0 2020
Slide 3: Safe Harbor
Safe Harbor This presentation has been prepared by the Zota Health Care Limited (the “Company”) only for information purpose to the stakeholders and does not contain any offer or invitation to subscribe the securities of the Company. No offering of securities shall be made except by means of offer d
Slide 4: Table Of Contents
Table Of Contents 1 Result Highlights & Operational Metrics 2 Davaindia 3 Industry Snapshot 4 Financial Summary 3
Slide 5: Qtr- Result Highlights & Operational Metrics
Qtr- Result Highlights & Operational Metrics
Slide 6: Consol Quarterly Financial Highlights
Consol Quarterly Financial Highlights Q-o-Q 2816.64 33.66% 115.13 101.71 1754.96 85.24 51.05 33.56% Q2-FY21 Q1-FY21 Q2-FY21 Q1-FY21 Q2-FY21 Q1-FY21 Q2-FY21 Q1-FY21 Revenues (Rs Lakhs) Gross Profit (%) Operating Profit (Rs Lakhs) PAT (Rs Lakhs) Y-o-Y 33.56% 141.94 109.07 2816.64 85.24 101.71 2528.75
Slide 7: Revenue Break up – Quarterly
Revenue Break up – Quarterly Domestic Sales 1879.70 DavaIndia Sales 1556.58 574.97 1056.23 370.00 307.00 Q2-FY21 Q1-FY21 Q2-FY20 Q2-FY21 Q1-FY21 Q2-FY20 Export Sales (SEZ) 685.09 328.73 342.00 Q2-FY21 Q1-FY21 Q2-FY20 6
Slide 8: Consol Profit & Loss Statement - Quarterly
Consol Profit & Loss Statement - Quarterly Particulars (Rs Lakhs) Q2FY21 Q2FY20 YoY % QoQ % Q1FY21 Export Sales (SEZ) 685.09 342 100% 108% 328.73 Dava India Sales 574.97 307 87% 55% 370 Domestic Sales 1556.58 1,879.70 -17% 47% 1,056.23 Revenues from Operations 2,816.64 2,528.70 11% 60% 1,754.96 Cost
Slide 9: Management Commentary
Management Commentary • After the COVID-19 outbreak and a one-time hiccup in the performance of the company in Q1FY21, the company has made a strong recovery in Revenue from Operations across all three segments in Q2FY21. In fact new-age businesses of the company i.e. Dava India and Exports recorded
Slide 10: Management Commentary Domestic Operations Exports
Management Commentary Domestic Operations • Domestic operations of the company have made a major recovery after the COVID-19 Lockdown, on a Q-o-Q basis the Revenue from Operations grew 49%, while the operations are still down 2.5% on a Y-o-Y basis – the management is confident of making a strong rec
Slide 11: DavaIndia Generic Pharmacy
healthcare Itd. GY davaindia’ GENERIC PHARMACY
Slide 12: Davaindia Key Figures
Davaindia Key Figures SKU’s 1353 1368 1310 1333 1338 1250 1050 1100 1150 Q2-FY19 Q3-FY19 Q4-FY19 Q1-FY20 Q2-FY20 Q3-FY20 Q4-FY20 Q1-FY21 Q2-FY21 Stores rolled-out 99 45 39 33 32 31 28 29 29 Q2-FY19 Q3-FY19 Q4-FY19 Q1-FY20 Q2-FY20 Q3-FY20 Q4-FY20 Q1-FY21 Q2-FY21 11
Slide 13: Davaindia Key Figures
Davaindia Key Figures Average Wallet Spend No. of Customers Served 181 159 164 152 338415 352623 132 136 126 113 116 259022 267030 275520 231100 221975 90400 83925 Q2-FY19 Q3-FY19 Q4-FY19 Q1-FY20 Q2-FY20 Q3-FY20 Q4-FY20 Q1-FY21 Q2-FY21 Q2-FY19 Q3-FY19 Q4-FY19 Q1-FY20 Q2-FY20 Q3-FY20 Q4-FY20 Q1-FY21
Slide 14: During the quarter Davaindia has catered 3.52 lakhs customers
• During the quarter Davaindia has catered 3.52 lakhs customers and impact of the same can be seen on revenue side, during the quarter Davaindia has registered rebust growth in Q2FY21 at 87% YoY. • Davaindia has witnessed turn around of patients to generic medicines from the branded counterparts, Ti
Slide 15: 14
14
Slide 16: Davaindia Footprints
Davaindia Footprints KASHMIR (2) HIMACHAL PRADESH (3) PUNJAB (5) HARYANA (11) NEW DELHI (16) Yamunanagar, Kurukshetra, Bhiwani, Hisar,Faridabad, UTTARAKHAND (3) Yamunanagar, Panipat Dehradun, Araghar RAJASTHAN (15) ) Jodhpur, Sikar, Shri AASAM (2) Jaipur, Ganganagar, Nagpur, UTTAR PRADESH (34) Bhara
Slide 17: Industry Snapshot
Industry Snapshot
Slide 18: India's Retail 'Generic Medicine' Landscape
India‘s Retail ‘Generic Medicine’ Landscape Our Honourable Prime Minister launched ‘Jan Aushadhi Ken Jan Aushadhi Stores -A key initiative against t he high priced selling medicines in the market Jan Aushadhi Stores rolled-out 1 dras’ under the ‘Pradhan Mantri Bhartiya JanaushahiPariyoj ana’ (PMBJP)
Slide 19: Underpenetrated Generic Medicine Market
Underpenetrated Generic Medicine Market 4 pillars to drive healthcare Branded and generic mix of Indian pharma market 18
Slide 20: Financial Summary
ml ae Financial Summary A Zoid
Slide 21: Profit & Loss Statement
Profit & Loss Statement Particulars (INR Lakhs) FY15 FY16 FY17 FY18 FY19 FY20 Q2FY21 Income from Operations 5,646.30 6,473.30 7,158.00 7,785.20 8,562.90 9,511.30 2,816.64 Other Income 1.4 7.7 5.6 151.9 154.5 151.3 21.1 Total Income 5,647.80 6,481.00 7,163.60 7,937.00 8,717.40 9,662.60 2,837.74 Opera
Slide 22: Balance Sheet & Key Ratios
Balance Sheet & Key Ratios Particulars (INR Lakhs) FY14 FY15 FY16 FY17 FY18 FY19 FY20 H1FY21 Share capital 1,196.9 1,436.3 1,436.3 1,436.3 1,754.3 1,754.3 2,456.0 2,456.0 Reserves and Surplus 384.2 395.7 707.8 1,262.0 5,223.4 5,138.2 4,426.9 4,590.0 Non-current liabilities 521.3 548.7 272.7 466.8 64
Slide 23: Thank You
Contact Information Mr. Himanshu Zota / Mr. Ashvin Variya "ZOTA HOUSE", 2/896, Hira Modi Street, Sagrampura, Surat-395 002(Gujarat) cszota@zotahealthcare.com www.zotahealthcare.com Thank You